Project Description Our research focuses on the role of the gut microbiome in various conditions, including alcohol-associated liver disease, metabolic dysfunction-associated steatotic liver disease, liver fibrosis, inflammatory bowel disease, and colon and liver cancers. Additionally, we explore the therapeutic potential of cannabidiol in treating liver diseases and neurological disorders. A key area of interest […]

Project Description Aging and Prostate Cancer: Dr. Zhang has a long-standing interest in prostate cancer, particularly in aging’s contribution to prostate carcinogenesis and the efficacies of candidate aging-associated prostate cancer interventions. We are currently working on (1) identifying associations between Th17/Treg ratio alteration and human PCa progression associated with advanced aging; (2) defining how aging-associated […]

Project Descriptions Interleukin-17 in Prostate Cancer. A major focus of our research program is to understand the role of inflammation in cancer initiation, promotion, and progression. Our target molecule in inflammation is interleukin-17 (IL-17). IL-17 is a key cytokine in many inflammatory and autoimmune diseases. We are using in-vitro and in-vivo (transgenic and knockout mice) approaches […]

Lab Description Her first major discovery involved identification of novel mechanisms attenuating expression and damage caused by LINE-1 retrotransposons. She was a key contributor to the establishment of somatic expression of LINE-1 in many normal human tissues, a finding that has triggered a broad recognition of somatic LINE-1 damage and its relevance to human disease […]

Project Description The primary focus of Dr. Hill’s research is the molecular mechanisms of signal transduction cross- talk in breast cancer. Breast cancer is an endocrine-responsive neoplasm and as such is responsive to a variety of endocrine and growth factor stimuli. A complete understanding of the factors regulating the proliferation breast cancer, as well as […]

Lab Description Despite the recent development and FDA approval of new hormone therapy drugs for metastatic castration-resistant prostate cancer, disease progression after hormone therapies remains the most critical challenge in the clinical management of prostate cancer. Emerging evidences indicate that prostate cancers can adapt to all current hormone therapies by signaling through constitutively-active androgen receptor […]